MoonLake Immunotherapeutics Class A Ordinary Shares
MLTXStock
$19.01−61.62%52W
Market Cap$1.65B
P/E—
Div yield—
Beta1.08
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)66.08%
Price vs S&P 500 (4W)2.12%
VGM Score55.66
Market Capitalization$1.65B
Earnings Surprise History
Q1 26-0.98est. -0.91
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
3.95
3.95
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares | — | — | C | $19.01 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a tri-specific Nanobody that inhibits IL-17A and IL-17F to treat inflammatory skin and joint diseases. Clinical data suggest SLK has potential for disease modification in dermatology and rheumatology indications where IL-17A and IL-17F drive pathophysiology.